Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Rare Disease Treatment Market
Rare Disease Treatment Market - By Drug (Biologics, Non-biologics), By Therapeutic Area (Cancer, Blood-related Disorders, Central Nervous System, Respiratory Disorders) Patient, Route of Administration & Forecast, 2023-2032
- Report ID: GMI3873
- Published Date: Jan 2023
- Report Format: PDF
Rare Disease Treatment Market Size
Rare Disease Treatment Market size reached over USD 195 billion in 2022 and is anticipated to exhibit more than 8.5% CAGR through 2023-2032, owing to the increasing drug research and approval.
Given the growing burden of rare diseases, federal government agencies are emphasizing drug approvals through grant administrations for treatment research. For instance, in 2020, the U.S. FDA approved drugs to treat a disease with bladder dysfunction called neurogenic detrusor overactivity, observed in patients with spinal cord injury and multiple sclerosis. The pharma sector has also been targeting treatment commercialization through growing focus on the novelty of the mechanism of action compared to traditional medications. The rapid introduction of therapeutic molecular medicines will therefore create lucrative growth prospects for rare disease treatment centers worldwide.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| Rare Disease Treatment Market Size in 2022: | USD 195 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR: | 8.6% |
| 2032 Value Projection: | USD 453 Billion |
| Historical Data for: | 2018 to 2022 |
| No. of Pages: | 225 |
| Tables, Charts & Figures: | 352 |
| Segments covered: | Drug, Therapeutic Area, Patient, Route of Administration, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Despite the growth trajectory, the high cost of rare disease therapies and drugs may assert a negative influence on the industry outlook to a certain extent. As per statistics from IQVIA, in 2020, the average cost for rare disease treatment per patient was estimated at around USD 32,000 per year. Patients with rare diseases also require accessible and adequate health coverage to maintain health for longer periods. These increased costs are mainly due to delayed drug imports and are likely to create roadblocks to rare disease treatment market progress to some extent.
Rare Disease Treatment Market Analysis
Non-biologics drug segment is set to register over 10% CAGR through 2032, on account of the immunogenicity and minimal side effects associated with such products. These drugs are deemed effective for treating certain conditions including APDS (activated phosphoinositide 3-kinase delta syndrome) and Felty Syndrome. These factors, alongside cost-effectiveness and non-complexity in clinical studies, are projected to augment the consumption of non-biologic medications among rare disease patients.
Rare disease treatment market value from the central nervous system (CNS) segment is expected to surpass USD 38 billion by 2032, given the rising prevalence of disorders that affect nerve cells in the spinal cord and brain, causing loss of muscle control. Based on data from the National Library of Medicine, amyotrophic lateral sclerosis affects around 5 in 100,000 people worldwide. Moreover, the strong focus on the development of precision medicines will further drive the demand for therapies to treat rare diseases.
Pediatric patient segment is anticipated to reach over USD 106 billion by 2032. This is on account of the growing incidence of Byler disease, a rare inherited condition due to a faulty gene causing liver failure in children. As per statistics from the UMPC Health data, this disease is estimated to affect 1 in 100,000 pediatric patients. With the availability of advanced therapies expanding rapidly, rare disease treatment solutions will gain considerable traction among the pediatric patient population.
Based on the route of administration, rare disease treatment market share from injectable segment is set to depict more than 9% CAGR through 2023-2032, given the high bioavailability of medications administered intravenously. Injectables also provide rapid effects, thereby gaining adoption for the treatment of disorders that need immediate intervention. As a result of the escalating need for accurate and effective therapeutics, the production of injectable orphan drugs will increase, contributing to the rare disease treatment industry dynamics over the forecast period.
Europe rare disease treatment industry size will exceed USD 115.5 billion by 2032, owing to the rising disease burden and the shifting preference toward early disease diagnosis. Based on data from the European Commission, in 2021, nearly 36 million people were diagnosed with rare diseases in Europe. Such factors are likely to drive up the demand for accurate solutions for early diagnosis, creating strong growth avenues for the rare disease treatment market. Furthermore, the increasing rate of hospitalization and the presence of supportive healthcare policies will proliferate the acceptance of rare disease therapies across the region.
Rare Disease Treatment Market Share
- Vertex Pharmaceuticals Incorporated
- GlaxoSmithKline plc.
- F. Hoffman-La-Roche Ltd.
- Eli Lilly and Company
- BioMarin
- Bristol-Myers Squibb
- Sanofi
- Pharmacyclics LLC
- Biogen
- Pfizer Inc.
- Novartis AG
- Merck
- Johnson & Johnson
- Bayer AG
- Amgen Inc.
- Alexion Pharmaceuticals
- AstraZeneca plc
- Seagen Inc.
- AbbVie Inc.
are some of the prominent players in the rare disease treatment market. These companies are focusing on new treatment launches and business expansions to increase their consumer base in the global market.
Impact of the COVID-19 pandemic
Due to the COVID-19-induced economic disruptions and lockdowns, many patients with rare diseases were forced to postpone their therapeutic interventions, asserting an adverse impact on the rare disease treatment industry outlook. Despite such setbacks, rapid medical technology advancements, drug approvals, and patent expirations have boosted the availability of both generic and branded drugs in recent years. Additionally, the rising adoption of telehealth services in the post-pandemic period will also support the growth of rare disease treatment service providers over the foreseeable future.
Rare disease treatment market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments: Click here to Buy Section of this Report
By Drug
- Biologics
- Non-biologics
By Therapeutic Area
- Cancer
- Blood-related Disorders
- Central Nervous System (CNS)
- Respiratory Disorders
- Musculoskeletal Disorders
- Cardiovascular Disorders
- Others
By Patient
- Adult
- Pediatric
By Route of Administration
- Oral
- Injectable
The above information is provided for the following regions and countries:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Poland
- Switzerland
- Sweden
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Indonesia
- Thailand
- Vietnam
- Latin America
- Brazil
- Mexico
- Argentina
- Chile
- Colombia
- Peru
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Israel
- Iran
- Egypt
Frequently Asked Questions (FAQ) :
Rare Disease Treatment Market Scope
